Fludarabine-based regimens in relapsed or refractory CLL
Study . | Treatment and regimen . | No. patients* . | Refractory, %† . | OR, % . | CR, % . | OR, % refractory . |
|---|---|---|---|---|---|---|
| O'Brien et al (2001)61 | Fludarabine 30 mg/m2 intravenously d 1-3, for 4-6 w, up to 6 courses; cyclophosphamide 300-500 mg/m2 intravenously d 1-3 | 94 | 69 | 80 | 12 | 39 |
| Hallek et al (2001)62 | Fludarabine 30 mg/m2 intravenously d 1-3, for 28 d, up to 6 courses; cyclophosphamide 250 mg/m2 intravenously d 1-3 | 18 | — | 94 | 11 | — |
| Bosch et al (2002)63 | Fludarabine 25 mg/m2 intravenously d 1-3 for 28 d, up to 6 courses; cyclophosphamide 200-600 mg/m2 intravenously d 1-3; mitoxantrone 6-8 mg/m2 d 1 | 60 | 58 | 78 | 50 | 34 |
| Mauro et al (2002)64 | Fludarabine 25 mg/m2 intravenously d 1-3, for 28 d, up to 6 courses; Ara-C 1 g/m2 d 1-2; novantrone 10 mg/m2 d 1; dexamethasone 20 mg intravenously d 1-3 | 23 | 60 | 70 | 48 | 50 |
| Schulz et al (2002)65 | Fludarabine 25 mg/m2 intravenously d 1-5 for 28 d, courses 1 to 4; rituximab 375 mg/m2 intravenously d 1 for 28 d, courses 3 to 7 | 11 | — | 90 | 27 | — |
| Wierda et al (2005)66 | Fludarabine 25 mg/m2 intravenously d 1-3, for 28 d, up to 6 courses; cyclophosphamide 250 mg/m2 intravenously d 1-3; rituximab 375-500 mg/m2 d 1 intravenously | 177 | 18‡ | 73 | 25 | 58 |
Study . | Treatment and regimen . | No. patients* . | Refractory, %† . | OR, % . | CR, % . | OR, % refractory . |
|---|---|---|---|---|---|---|
| O'Brien et al (2001)61 | Fludarabine 30 mg/m2 intravenously d 1-3, for 4-6 w, up to 6 courses; cyclophosphamide 300-500 mg/m2 intravenously d 1-3 | 94 | 69 | 80 | 12 | 39 |
| Hallek et al (2001)62 | Fludarabine 30 mg/m2 intravenously d 1-3, for 28 d, up to 6 courses; cyclophosphamide 250 mg/m2 intravenously d 1-3 | 18 | — | 94 | 11 | — |
| Bosch et al (2002)63 | Fludarabine 25 mg/m2 intravenously d 1-3 for 28 d, up to 6 courses; cyclophosphamide 200-600 mg/m2 intravenously d 1-3; mitoxantrone 6-8 mg/m2 d 1 | 60 | 58 | 78 | 50 | 34 |
| Mauro et al (2002)64 | Fludarabine 25 mg/m2 intravenously d 1-3, for 28 d, up to 6 courses; Ara-C 1 g/m2 d 1-2; novantrone 10 mg/m2 d 1; dexamethasone 20 mg intravenously d 1-3 | 23 | 60 | 70 | 48 | 50 |
| Schulz et al (2002)65 | Fludarabine 25 mg/m2 intravenously d 1-5 for 28 d, courses 1 to 4; rituximab 375 mg/m2 intravenously d 1 for 28 d, courses 3 to 7 | 11 | — | 90 | 27 | — |
| Wierda et al (2005)66 | Fludarabine 25 mg/m2 intravenously d 1-3, for 28 d, up to 6 courses; cyclophosphamide 250 mg/m2 intravenously d 1-3; rituximab 375-500 mg/m2 d 1 intravenously | 177 | 18‡ | 73 | 25 | 58 |
— indicates not reported.
Only refers to relapsed or refractory patients included in these series
Definition of refractoriness: resistance to the previous treatment including alkylating agents or fludarabine
Fludarabine refractory patients defined as failure to achieve at least a PR with the last fludarabine-based treatment or progression within 6 months of treatment